Testing Multiple Behavioral Science Strategies to Increase Flu-Shot Rates
Influenza, Human
Bottom Line
View on ClinicalTrials.gov: NCT04565353 ↗Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Flu shot text messages (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Pennsylvania
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Flu Shot Receipt at or Before Appointment |
1113; 1210; 1150; 1163; 1183; 1200 | — |
| SECONDARY Number of Participants With Flu Shot Receipt Before March 31, 2021 |
1296; 1391; 1330; 1343; 1338; 1371 | — |
Summary
Eligibility Criteria
Penn Medicine and Geisinger patients will be included if they:
Inclusion Criteria
- Have a cell phone number recorded in a Penn Medicine or Geisinger database
- Have a new or routine primary care appointment during the study recruitment period (not a sick visit)
Exclusion Criteria
- Have documentation of allergy or adverse event to influenza vaccination in medical records
- Have documentation of already receiving their 2020 influenza vaccination prior to randomization in medical records
- Have opted out of receiving text message appointment reminders
- Have asked not to be contacted for research purposes
- Have an appointment with someone other than their primary care physician
- Have an appointment with someone other than a physician, resident, nurse practitioner, or physician assistant
We will recruit as many patients as possible starting in September 2020. We will stop enrolling participants with appointments scheduled to occur after December 31, 2020 if we have reached 4,000 participants per condition. If we do not have 4,000 participants per condition by December 31, 2020, we will continue enrolling participants until we have reached 4,000 per condition, or until March 31, 2021 (discontinuing enrollment at whichever milestone arrives sooner - 4,000 people enrolled or 3/31/21).
Data sourced from ClinicalTrials.gov (NCT04565353). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.